PMID- 25384804
OWN - NLM
STAT- MEDLINE
DCOM- 20150205
LR  - 20141111
IS  - 1121-421X (Print)
IS  - 1121-421X (Linking)
VI  - 60
IP  - 4
DP  - 2014 Dec
TI  - Benefit of supplements in functional dyspepsia after treatment of Helicobacter 
      pylori.
PG  - 263-8
AB  - AIM: Functional dyspepsia, though benign, leads to deterioration of the quality 
      of life and high costs for healthcare systems. The optimal therapy for functional 
      dyspepsia is still to be defined because of its multifactorial pathogenesis. In 
      an open multicentric study of patients with functional dyspepsia, we 
      prospectively evaluated the benefit of treatment with a food supplement composed 
      of sodium alginate, carbonate calcium, pineapple, papaya, ginger, alpha-galactosidase 
      and fennel (Perdiges, Bioten Snc, Turin, Italy). METHODS: Ninety-one consecutive 
      patients were included, suffering from functional dyspepsia, who had been 
      previously submitted to therapy to eradicate the infection from Helicobacter 
      pylori (H. pylori) and were waiting to perform the Urea Breath Test (UBT). The 
      primary goal was to establish the percentage of patients who continued to abstain 
      from proton pump inhibitors (PPI) as they waited to carry out the UBT, 
      differentiating between patients who were treated (N.=55) with Perdiges and those 
      who were not (N.=36). Our secondary goal was to document the differences within 
      the 2 groups in terms of symptoms perceived between the start and end of the 
      observation period. The wellness reported, during or in absence of treatment with 
      Perdiges, was evaluated by the use of the VAS scale (Visual Analogical Scale) 
      completed before the start of the treatment and after 30 days. RESULTS: All the 
      patients treated with Perdiges (55/55, 100%) and 31/36 (86.1%) patients who were 
      not (P=0.008) continued to abstain from PPI in the period awaiting the UBT. The 
      VAS scale of those who took Perdiges improved on average by 1.78 points versus a 
      worsening of 0.08 points of those who did not take it (P<0.0001). Furthermore, 
      while among those who took Perdiges there was a statistically significant 
      improvement (P<0.0001) in the VAS scale, between the baseline and the end of 
      treatment, a worsening of 0.08 points (P=0.78) was noticed among the patients who 
      did not take it. CONCLUSION: Perdiges is significantly effective in the period 
      following treatment to eradicate the infection from H. pylori in patients with 
      functional dyspepsia. This allows to reduce the need to use antisecretive drugs. 
      Further randomised studies, with wide ranging case histories, must assess its 
      long-term efficacy.
FAU - Pellicano, R
AU  - Pellicano R
AD  - Department of Gastroenterology and Hepatology San Giovanni Battista (Molinette) 
      Hospital Turin, Italy - rinaldo_pellican@hotmail.com.
FAU - Ribaldone, D G
AU  - Ribaldone DG
FAU - Saracco, G M
AU  - Saracco GM
FAU - Leone, N
AU  - Leone N
FAU - De Angelis, C
AU  - De Angelis C
FAU - Arrigoni, A
AU  - Arrigoni A
FAU - Morello, E
AU  - Morello E
FAU - Sapone, N
AU  - Sapone N
FAU - Cisaro, F
AU  - Cisaro F
FAU - Astegiano, M
AU  - Astegiano M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PL  - Italy
TA  - Minerva Gastroenterol Dietol
JT  - Minerva gastroenterologica e dietologica
JID - 9109791
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Perdiges)
RN  - 0 (Plant Preparations)
RN  - 0 (Proton Pump Inhibitors)
RN  - 12001-76-2 (Vitamin B Complex)
RN  - 6SO6U10H04 (Biotin)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/administration & dosage/adverse effects
MH  - Biotin/therapeutic use
MH  - *Dietary Supplements
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Dyspepsia/*drug therapy/etiology/microbiology
MH  - Female
MH  - Follow-Up Studies
MH  - Helicobacter Infections/drug therapy
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Plant Preparations/*therapeutic use
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/administration & dosage/adverse effects
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Visual Analog Scale
MH  - Vitamin B Complex/therapeutic use
EDAT- 2014/11/12 06:00
MHDA- 2015/02/06 06:00
CRDT- 2014/11/12 06:00
PHST- 2014/11/12 06:00 [entrez]
PHST- 2014/11/12 06:00 [pubmed]
PHST- 2015/02/06 06:00 [medline]
AID - R08Y2014N04A0263 [pii]
PST - ppublish
SO  - Minerva Gastroenterol Dietol. 2014 Dec;60(4):263-8.